NO132692B - - Google Patents
Download PDFInfo
- Publication number
- NO132692B NO132692B NO15123463A NO15123463A NO132692B NO 132692 B NO132692 B NO 132692B NO 15123463 A NO15123463 A NO 15123463A NO 15123463 A NO15123463 A NO 15123463A NO 132692 B NO132692 B NO 132692B
- Authority
- NO
- Norway
- Prior art keywords
- kanamycin
- riboflavin
- isolated
- phosphate
- salt
- Prior art date
Links
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 32
- 229960000318 kanamycin Drugs 0.000 claims description 26
- 229930182823 kanamycin A Natural products 0.000 claims description 26
- 229930027917 kanamycin Natural products 0.000 claims description 22
- 239000008280 blood Substances 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 239000004228 Riboflavin-5'-Phosphate Substances 0.000 claims description 6
- 239000011768 flavin mononucleotide Substances 0.000 claims description 6
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 claims description 5
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 2
- WGPLDEKGFWYWFG-UHFFFAOYSA-N 2-(2-hydroxyethylamino)ethanol dihydrate Chemical compound O.O.OCCNCCO WGPLDEKGFWYWFG-UHFFFAOYSA-N 0.000 claims 1
- 239000000725 suspension Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- CSGQJHQYWJLPKY-UHFFFAOYSA-M 2-hydroxy-6-oxo-1h-pyridine-4-carboxylate Chemical compound OC1=CC(C([O-])=O)=CC(=O)N1 CSGQJHQYWJLPKY-UHFFFAOYSA-M 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229960001192 bekanamycin Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229930182824 kanamycin B Natural products 0.000 description 3
- SKKLOUVUUNMCJE-FQSMHNGLSA-N kanamycin B Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SKKLOUVUUNMCJE-FQSMHNGLSA-N 0.000 description 3
- 229960002064 kanamycin sulfate Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RWVDCJCCHSXYRO-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;hydroxide Chemical compound [OH-].OCC[NH2+]CCO RWVDCJCCHSXYRO-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/04—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
- C07D501/06—Acylation of 7-aminocephalosporanic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
- C07D501/32—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by an araliphatic carboxylic acid, which is substituted on the aliphatic radical by hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1352462A SE311519B (da) | 1962-12-14 | 1962-12-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO132692B true NO132692B (da) | 1975-09-08 |
| NO132692C NO132692C (da) | 1975-12-17 |
Family
ID=20297538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO15123463A NO132692C (da) | 1962-12-14 | 1963-12-13 |
Country Status (6)
| Country | Link |
|---|---|
| DE (1) | DE1445434A1 (da) |
| DK (1) | DK121231B (da) |
| FI (1) | FI42332C (da) |
| GB (1) | GB1073530A (da) |
| NO (1) | NO132692C (da) |
| SE (1) | SE311519B (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA695612B (en) * | 1968-08-23 | 1971-03-31 | Lilly Co Eli | Preparation of cephalosporin compounds |
| CS165353B2 (da) * | 1969-12-18 | 1975-12-22 | ||
| US3694437A (en) * | 1970-08-19 | 1972-09-26 | Lilly Co Eli | Process for preparing cephalosporin compounds |
| US4024134A (en) * | 1971-01-29 | 1977-05-17 | Glaxo Laboratories Limited | Syn isomers of cephalosporins having α-hydroximino- or α-acyloxyiminoacylamido groups at position-7 |
| IE36041B1 (en) * | 1971-01-29 | 1976-08-04 | Glaxo Lab Ltd | Improvements in or relating to antibiotics |
| GB1389194A (en) * | 1971-01-29 | 1975-04-03 | Glaxo Lab Ltd | Antibiotics |
| US4209616A (en) * | 1971-01-29 | 1980-06-24 | Glaxo Laboratories Limited | Syn isomers of cephalosporins having α-hydroximino- or α-acyloxyiminoacylamido groups at position-7 |
| CH579571A5 (da) * | 1971-05-14 | 1976-09-15 | Glaxo Lab Ltd | |
| GB1399086A (en) * | 1971-05-14 | 1975-06-25 | Glaxo Lab Ltd | Cephalosporin compounds |
| BE793595A (fr) * | 1972-01-03 | 1973-07-02 | Hoffmann La Roche | Derives acyles |
| GB1472534A (en) * | 1973-07-06 | 1977-05-04 | Glaxo Lab Ltd | 7beta-hydroxyiminoacylamido-cephalosporins |
| NL162387C (nl) * | 1977-09-06 | 1980-05-16 | Gist Brocades Nv | Werkwijze voor het bereiden van 6-(d-alpha-amino-p- -hydroxyfenylacetamido)penicillanzuur. |
| US4316017A (en) | 1979-03-19 | 1982-02-16 | Bristol-Myers Company | Cephalosporin intermediates |
| US4316016A (en) | 1979-03-19 | 1982-02-16 | Bristol-Myers Company | Cephalosporin intermediates |
| US4223135A (en) | 1979-03-19 | 1980-09-16 | Bristol-Myers Company | Production of cephalosporins |
| GB9423459D0 (en) * | 1994-11-21 | 1995-01-11 | Biochemie Gmbh | Silylation process |
| AT402928B (de) * | 1994-12-23 | 1997-09-25 | Biochemie Gmbh | Neues verfahren zur herstellung von cefotaxim |
-
1962
- 1962-12-14 SE SE1352462A patent/SE311519B/xx unknown
-
1963
- 1963-11-28 DE DE19631445434 patent/DE1445434A1/de active Pending
- 1963-12-13 DK DK582163A patent/DK121231B/da unknown
- 1963-12-13 NO NO15123463A patent/NO132692C/no unknown
- 1963-12-13 FI FI246763A patent/FI42332C/fi active
- 1963-12-16 GB GB4967663A patent/GB1073530A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FI42332B (da) | 1970-03-31 |
| NO132692C (da) | 1975-12-17 |
| GB1073530A (en) | 1967-06-28 |
| DK121231B (da) | 1971-09-27 |
| DE1445434A1 (de) | 1969-01-16 |
| SE311519B (da) | 1969-06-16 |
| FI42332C (fi) | 1970-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO132692B (da) | ||
| AT392472B (de) | Verfahren zur herstellung eines stabilen kristallinen di- oder trihydrats der 7beta- ((z)-2-(2-aminothiazol-4-yl)-4-carboxybut-2- enoylamino)-3-cephem-4-carbonsaeure | |
| DE2332878A1 (de) | Salze von sauren cephalosporinen mit arginin und lysin, ihre herstellung und verwendung | |
| EA001376B1 (ru) | Новые производные эритромицина, способ их получения и их применение в качестве медикаментов | |
| AT366050B (de) | Verfahren zur herstellung einer hydratisierten kristallinen form des natriumsalzes eines oximderivates der 7-aminothiazolylacetamidocephalospo-ransaeure | |
| PL109311B1 (en) | Method of producing stabilized sodium salt of 7-/d-2-formyloxy-2-phenyloacetamido/-3-/methylo-1h-tetrazolylo-5-thiomethylo/-3-cephemocarboxylic-4 acid | |
| US4935406A (en) | Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders | |
| DD275871A5 (de) | Verfahren zur herstellung von derivaten von 9-deoxo-9a-aza-9a-homoerythromycin a | |
| EP0122585A2 (de) | Neue Kristallmodifikation von Ceftazidim | |
| US2756226A (en) | Acid-stable penicillins | |
| DE2234280B2 (de) | Cephalosporinverbindungen und Verfahren zu deren Herstellung | |
| EP0348143A2 (en) | Bismuth derivatives of saccharide phosphates and sulphates | |
| US2881163A (en) | Process of preparing salts | |
| US3862186A (en) | Process for the production of cephalexin monohydrate | |
| DE814316C (de) | Verfahren zur Herstellung von Streptomycin- und Dihydrostreptomycinsalzen | |
| DE2645144C2 (de) | Cephalosporine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel | |
| US2580195A (en) | Method of purifying 4-aminosalicylic acid | |
| GB1561060A (en) | Crystalline sodium salt of cephacetrile | |
| US4482545A (en) | Isoefrotomycin, process of preparation, pharmaceutical composition and method of using same | |
| JPH0157115B2 (da) | ||
| GB757137A (en) | New adrenochrome derivative and process for its production | |
| Ågren | Nature of the Anti-Anaemic Factor (Castle) | |
| AT238377B (de) | Verfahren zur Herstellung des neuen O-Benzoylthiamin-disulfids | |
| DE2622985C3 (de) | Antibiotisches Mittel enthaltend 7- [D-a-Amino-a-(p-hydroxyphenyl) acetamido] -3-il,2,3-triazol-5ylthiomethyl)-3- cephem-4-carbonsäure und Verfahren zu seiner Herstellung | |
| DE2949065C2 (da) |